Register online | Log in | My Prescrire

Issue contents

• Current issue
• Last 12 issues
• All issues

Topics

• Annual Prescrire Awards
• Advancing healthcare policy
• Positions
• Mediator° - the criminal trial
• Drugs to avoid: 2026 update
• Spotlight

About Prescrire

• Editorial policies
• How we work
• AMP: non-profit
• Financing
• No conflicts of interest
• Where to find us
• About Prescrire International
• Citations in other journals
• A global network

Offers

• Subscribe or renew my subscription
• Solidarity Subscription Rate
• Subscribers: register online
• Prescrire's other products
• Free Special Edition
• Sign up to receive the newsletter

english.prescrire.org

Prescrire's other websites

Prescrire.org Formations Prescrire Prescrire Campus Éviter l'Évitable

In Prescrire's Spotlight

Public health under attack, in the US and beyond  Editorial  The scale and speed of the drastic changes brought about in the first few months of the second Trump presidency, in the US and around the world, have taken observers aback. Considerable damage has already been done in the public health sphere, and more is set to come. In Europe, these drastic changes are being echoed in a number of harmful initiatives. Full article available for download (FREE) 1 June 2026

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Recombinant chikungunya vaccine (Vimkunya°)  Marketing Authorisations  An attenuated chikungunya vaccine (i.e. containing a live attenuated strain of the chikungunya virus) was authorised in the European Union in 2024. Another chikungunya vaccine was authorised in 2025. It consists of viral proteins produced in cell culture, and an aluminium-based adjuvant.   Full article available for download by subscribers 1 June 2026

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Sparsentan (Filspari°) in immunoglobulin A nephropathy  Marketing Authorisations  Sparsentan has been authorised in the European Union for use in adult patients with primary immunoglobulin A nephropathy with proteinuria. In this situation, does sparsentan slow disease progression and delay the onset of end-stage kidney disease? And what are its adverse effects?   Full article available for download by subscribers 1 June 2026

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ In-utero exposure to lamotrigine: better elucidated consequences  Adverse Effects  In 2019, lamotrigine was the most thoroughly evaluated antiepileptic drug in terms of the consequences of in-utero exposure, and it seemed to be the least teratogenic antiepileptic. The rate of major malformations associated with doses below 300 mg per day was similar to that observed in the general population. In the long term, in-utero exposure to lamotrigine seemed to increase the incidence of neurodevelopmental disorders. What more is known in 2026 about the consequences of in-utero exposure to lamotrigine? Full article available for download by subscribers 1 June 2026

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ European fines for anti-generic strategies: when will penalties get tougher?  Outlook  Anti-competitive strategies are designed to delay the market introduction of copies (generics and biosimilars) of originator drugs, which are a major source of savings for third-party payers. Their significant impact on national finances is only marginally mitigated by the amounts of the fines imposed on pharmaceutical companies, which are a pittance in comparison to their revenues. Full article available for download by subscribers 1 June 2026

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Prescrire's finances: 2025 annual report  Outlook  Association Mieux Prescrire (AMP), the legal entity that publishes Prescrire's print and digital publications and educational programmes, makes its accounts public every year. The summary of its 2025 annual financial report is publicly available here. Full article available for download (FREE) 1 June 2026

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Biotechnologies: proposed European legislation underpinned by a biased approach  Advancing Healthcare Policy  Prescrire has warned the European Commission about the risks associated with reducing the regulatory requirements on drugs and medical devices derived from biotechnology. Full article available for download (FREE) 1 June 2026

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Enjoy these features, and more, in our upcoming issues COMING SOON• Elafibranor in primary biliary cholangitis • Oral semaglutide in type 2 diabetes: new data • In-utero exposure to mesalazine • Extending drug shelf life: potential benefits  > Subscribe now 1 June 2026

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ New! "2025 Free Special Edition", from the editors of Prescrire International  FREE SPECIAL EDITION  Check out this selection of articles to introduce you to Prescrire International, a wholly independent monthly drug bulletin, written by and for healthcare professionals. Includes an array of articles from the past year on drugs and health policy in Europe. > Click here for your free copy 1 January 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Subscribe today for full access to top-quality content from Prescrire International  SUBSCRIBE NOW!  Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 165 euros (less for students and residents of lower-income countries). 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Follow Prescrire International on LinkedIn and Facebook Keep up with the latest from Prescrire's editors, and support our values of independence and quality information, first and foremost in the interest of patients. Click here to > Follow us on LinkedIn or > Follow us on Facebook 1 January 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Receive the free, monthly "Independent Drug & Healthcare Newsletter" Click here to sign up for the free Newsletter from the editors of the non-profit journal Prescrire International, with highlights of the contents of the latest issue. 1 July 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Drugs to avoid, in the name of better patient care   DRUGS TO AVOID - 2026 UPDATE  Independent French medical journal Prescrire has published its annual update of drugs to avoid. The goal is to make it easier to choose high-quality care, and to prevent disproportionate harm to patients. > Read more

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Read more All the subjects in Prescrire's Spotlight >

• Sitemap |
• Terms of use |
• Contact
• |Top of page

---